Activities of José Inácio FARIA related to 2018/0161(COD)
Plenary speeches (1)
Supplementary protection certificate for medicinal products (A8-0039/2019 - Luis de Grandes Pascual) PT
Amendments (26)
Amendment 19 #
Proposal for a regulation
Recital 2
Recital 2
(2) By providing for a period of supplementary protection of up to five years, Regulation (EC) No 469/2009 seeks to promote, within the Union, the research and innovation that is necessary to develop medicinal products, and to contribute to Regulation (EC) No 469/2009 provided a uniform solution at Community level to prevent a heterogeneous evolution of national legislation creating new disparities, which could hinder the free movement of medicines within the Community and thus directly affect the functioning of the internal market. However, the medicines system in the EU has evolved in recent decades with the introduction of generic and biosimilar medicines which impreoventing the relocation of pharmaceutical research outside the Union to countries that may offer greater protection competitiveness, the sustainability of health systems and European citizens’ access to medicines, while the exception intended by the proposed amendment of this regulation provides an opportunity to improve the parameters referred to above, which are now under threat.
Amendment 23 #
Proposal for a regulation
Recital 2 a (new)
Recital 2 a (new)
(2a) The proposal to amend the regulation so as to allow the production of generics and biosimilars for export and storage to make it possible for them to enter the European market when the patent expires does not conflict with intellectual property rights, as they do not interfere with the duration of market exclusivity rights during the patent, which is underscored by the fact that immediate import is allowed after expiry, but represents a competitive disadvantage for the European generic medicines industry.
Amendment 33 #
Proposal for a regulation
Recital 4
Recital 4
(4) The absence of any exception in Regulation (EC) No 469/2009 to the protection conferred by a supplementary protection certificate has had the unintended consequence of preventing manufacturers of generics and biosimilars established in the Union from manufacturing, even for the exclusive purpose of exporting to third country markets in which such protection does not exist or has expired. A further unintended consequence is that the protection conferred by the certificate makes it more difficult for those manufacturers to enter the Union market immediately after expiry of the certificate, given that they are not in a position to build up production capacity until the protection provided by the certificate has lapsed, by contrast with manufacturers located in third countries where protection does not exist or has expired.
Amendment 47 #
Proposal for a regulation
Recital 7
Recital 7
(7) The aim of this Regulation is to ensure that manufacturers established in the Union are able to compete effectively in those third country markets where supplementary protection does not exist or has expired. It is intended to complement the efforts of the Union’s trade policy to ensure open markets for Union-based manufacturers of medicinal products. Indirectly, it is also intended to put those manufacturers in a better position to enter the Union market immediately after expiry of the relevant supplementary protection certificate. It would also help to serve the aim of fostering access to medicines in the Union by helping to ensure a swifter entry of generic and biosimilar medicines onto the market after expiry of the relevant certificate.
Amendment 48 #
Proposal for a regulation
Recital 8
Recital 8
(8) In thoese specific and limited circumstances, and in order to creatit is appropriate to eliminate the aforementioned, unintended side effects of the supplementary protection certificate so as to enable a level -playing field between Union-based manufacturers and those in third country manufacturers, it is appropriate to restrict the protection conferred by aies. This would enable making exclusively for: (i) export to third countries, and (ii) entry onto the union market immediately after expiry of the relevant supplementary protection certificate so, as to allow making for the exclusive purpose of export to third countries andwell as any related acts strictly necessary for that making or for the actual export itself or that entry onto the Union market.
Amendment 59 #
Proposal for a regulation
Recital 9
Recital 9
(9) That exception should cover the making of the product, including the product which corresponds to the medicinal product protected by a supplementary protection certificate protected by a supplementary protection certificate, including the making of the corresponding medicinal product, in the territory of a Member State, for the exclusive purpose of export to third countries, as well as any upstream or downstream acts by the maker or by third parties in a contractual relationship with the maker where no supplementary protection certificate is in place and to prepare for the entry in the Union's market on the first day after patent expiration, as well as any upstream or downstream acts, where such acts would otherwise require the consent of the certificate-holder, and are strictly necessary for making for the purpose of export or, for the actual export itself or for the entry in the Union's market on the first day after patent expiration. For instance, such acts may include the supply and import of active ingredients for the purpose of making the corresponding medicinal product, to which the product covered by the certificate corresponds, or temporary storage of the product or advertising for the exclusive purpose of export to third country destinemporary storage of the product or medicinal product, advertising or other activities necessary for the purpose of actually exporting to country destinations where no supplementary protection certificate is in place or the entry in the Union's market on the first day after patent expirations.
Amendment 67 #
Proposal for a regulation
Recital 10
Recital 10
(10) The exception should not cover placing thea medicinal product made for the exclusive purpose of export on the marketr for the entry in the Union's market on the first day after patent expiration in the Member State where a supplementary protection certificate is in force, either directly or indirectly after export, nor should it cover re-importation of the medicinal product to the market of a Member State in which a certificate is in force. Moreover, it should not cover any act or activity for the purpose of import of medicinal products, or parts of medicinal products, into the Union merely for the purposes of repackaging and re-exporting.
Amendment 72 #
Proposal for a regulation
Recital 11
Recital 11
(11) By limiting the scope of the exception to making for the purposes of export outside the Union andentry in the Union's market on the first day after patent expiration and export to countries where no supplementary protection certificate is in place as well as to prepare for the acts strictly necessary for such making or for the actual export itself, the exception introduced by this Regulation will not unreasonably conflict with normal exploitation of the product or medicinal product in the Member State where the certificate is in force, nor unreasonably prejudice the legitimate interests of the certificate-holder, taking account of the legitimate interests of third parties.
Amendment 80 #
Proposal for a regulation
Recital 12
Recital 12
Amendment 90 #
Proposal for a regulation
Recital 13
Recital 13
Amendment 104 #
Proposal for a regulation
Recital 14
Recital 14
Amendment 113 #
Proposal for a regulation
Recital 15
Recital 15
Amendment 120 #
Proposal for a regulation
Recital 19
Recital 19
Amendment 134 #
Proposal for a regulation
Recital 21
Recital 21
(21) It is necessary and appropriate for the achievement of the basic objective, of providing a level playing field for generic and biosimilar manufacturers with their competitors in third country markets where protection does not exist or has expired, to lay down rules restricting the exclusive right of a supplementary protection certificate holder to make the product in question during the term of the certificate, and also to impose certain information and labelling obligations on makers wishing to take advantage of those rulesenabling the making of the product in question during the term of the certificate. This Regulation complies with the principle of proportionality, and does not go beyond what is necessary in order to achieve the objectives pursued, in accordance with Article 5(4) of the Treaty on European Union.
Amendment 139 #
Proposal for a regulation
Recital 22
Recital 22
(22) This Regulation respects fundamental rights and observes the principles recognised by the Charter of Fundamental Rights of the European Union. In particular, this Regulation seeks to ensure full respect for the right to property in Article 17 of the Charter by maintaining the core rights of the supplementary protection certificate, by confining the exception to certificates granted on or after a specified date after entry into force of this Regulation and by imposing certain conditions on the application of the exceptionthe right to healthcare in Article 35 of the Charter by making medicines more accessible to EU patients, the principle of proportionality in Article 52 of the Charter, point (a) of Article 6 TFEU on the right to health protection for European citizens,
Amendment 144 #
2. The certificate referred to in paragraph 1 shall not confer protection against a particular acts against which the basic patent conferred protection if, with respect to that particular act, the following conditions are met:
Amendment 149 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 2 – point a – point i
Article 4 – paragraph 2 – point a – point i
(i) making for the exclusive purpose(s) of export to third countries; and/or entry into the market of Member States immediately after expiry of the certificate in those member states; and/or
Amendment 158 #
(ii) any related act that is strictly necessary for that making or for the actual export itself, for the export and/or for effectively entering the market of the Member States immediately after expiry of the certificate in those Member States;
Amendment 165 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 2 – point b
Article 4 – paragraph 2 – point b
Amendment 181 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 2 – point c
Article 4 – paragraph 2 – point c
Amendment 187 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 3
Article 4 – paragraph 3
Amendment 208 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 4
Article 4 – paragraph 4
Amendment 214 #
Proposal for a regulation
Article 1 – paragraph 1 – point 1
Article 1 – paragraph 1 – point 1
Regulation (EU) No 469/2009
Article 4 – paragraph 5
Article 4 – paragraph 5
5. Paragraph 2 shall apply in the case only of certificates granted on or after [OP: please insert the date of the first day of the third month that follows the month in which this amending Regulation is published in the Official Journal)].only to activities carried out after the entry into force of the present Regulation;
Amendment 223 #
Proposal for a regulation
Article 1 – paragraph 1 – point 2
Article 1 – paragraph 1 – point 2
Regulation (EU) No 469/2009
Article 11 – paragraph 4
Article 11 – paragraph 4
Amendment 229 #
Proposal for a regulation
Article 1 – paragraph 1 – point 4
Article 1 – paragraph 1 – point 4
Regulation (EU) No 469/2009
Article 21a – paragraph 4
Article 21a – paragraph 4
Amendment 231 #
Proposal for a regulation
Annex I
Annex I
Regulation (EU) No 469/2009
Annex I
Annex I